Provided by Tiger Trade Technology Pte. Ltd.

ASCENTAGE

36.360
-0.080-0.22%
Volume:1.59M
Turnover:57.88M
Market Cap:13.60B
PE:-8.96
High:37.860
Open:36.380
Low:35.920
Close:36.440
52wk High:95.350
52wk Low:30.000
Shares:374.00M
HK Float Shares:374.00M
Volume Ratio:0.79
T/O Rate:0.42%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-4.059
ROE:-154.56%
ROA:-23.02%
PB:8.83
PE(LYR):-8.96
PS:20.37

Loading ...

Analysts Are Bullish on Top Healthcare Stocks: Ascentage Pharma Group International (HK:6855), Kiora Pharmaceuticals (KPRX)

TIPRANKS
·
Jun 20

Ascentage Pharma Presents 17 Clinical Updates at European Hematology Meeting

MT Newswires Live
·
Jun 15

ASCENTAGE PHARMA GROUP (ASX: 06855) Discloses Multiple Clinical Advances at 2026 European Hematology Association Congress

Stock News
·
Jun 15

Ascentage Pharma presents updated Phase III POLARIS-1 data for olverembatinib in newly diagnosed Ph+ ALL at EHA 2026

Reuters
·
Jun 15

Ascentage Pharma (SEHK:6855) Stock After New ASCO 2026 Data A Fresh Look At Valuation

Simply Wall St.
·
Jun 14

Movement Alert|Ascentage Pharma Rises 5.42% in Regular Trading, Biotech Sector Rallies on Post-ASCO Momentum and RSU Share Purchases

Market Focus
·
Jun 12

Ascentage Pharma: Trustee Buys 110,000 Shares for 2022 RSU Scheme at HK$33.37 Each

Bulletin Express
·
Jun 11

ASCENTAGE PHARMA Group Acquires 110,000 Shares for 2022 Restricted Stock Unit Plan

Stock News
·
Jun 11

Ascentage Pharma: Trustee Purchases 190,000 Shares to Fund 2022 RSU Scheme

Bulletin Express
·
Jun 10

ASCENTAGE PHARMA GROUP Acquires 190,000 Shares Under 2022 Restricted Share Unit Plan

Stock News
·
Jun 10

GTHT Initiates Coverage on ASCENTAGE PHARMA GROUP with 'Add' Rating and HK$59.09 Target

Stock News
·
Jun 01

Ascentage Pharma reports 91.3% CCyR at 24 cycles for olverembatinib in second-line CML-CP study at ASCO 2026

Reuters
·
Jun 01

Ascentage Pharma reports early activity for alrizomadlin in pediatric solid tumor trial at ASCO 2026

Reuters
·
Jun 01

Ascentage Pharma reports Phase Ib data for olverembatinib-blinatumomab combo in Ph+ ALL, CML lymphoid blast phase at ASCO 2026

Reuters
·
Jun 01

Movement Alert|Ascentage Pharma Rises 6.35% in Regular Trading, B-Marker Removal Milestone Combined with ASCO Catalysts

Market Focus
·
May 29

Ascendage Pharma-B Reaches Milestone of Removing 'B' Label and Showcases Major Achievements at ASCO, Unleashing Global Innovation Value

Stock News
·
May 29

ASCENTAGE-B: Trustee Acquires 50,000 Shares for 2022 RSU Scheme at HK$38.20 Each

Bulletin Express
·
May 28

ASCENTAGE PHARMA GROUP-B Executes Share Purchase for Incentive Plan

Stock News
·
May 28

Ascentage Pharma trustee buys 50,000 shares for 2022 RSU scheme, pays HK$1.91 million

Reuters
·
May 28

Movement Alert|Ascentage Pharma Falls 6.24% in Regular Trading, Biotech Sector Broadly Under Pressure

Market Focus
·
May 28